

**S1 Table.** Individual patient characteristics and their responses and PFS at first-line chemotherapy according to the regimen

<b>Regimen</b>	<b>No. of patients</b>	<b>Age (yr)</b>	<b>Sex</b>	<b>Tumor location</b>	<b>Disease setting</b>	<b>Response</b>	<b>PFS (mo)</b>
<b>5-FU monotherapy</b>							
Infusional 5-FU/Leucovorin	12	58	Male	Head	Metastatic	SD	11.24
	16	70	Male	Head	Recurrent	PD	1.31
	17	58	Male	Head	Recurrent	PR	12.55
	27	67	Male	Body/tail	Locally Advanced	NA	0.10
Capecitabine	25	43	Female	Head	Locally Advanced	PR	20.07
	26	61	Male	Head	Locally Advanced	CR	14.49
<b>Gemcitabine monotherapy</b>							
	11	60	Male	Body/tail	Locally Advanced	SD	3.19
	14	53	Male	Head	Recurrent	NA	12.98
	15	29	Female	Body/tail	Metastatic	SD	3.09
	32	67	Male	Head	Recurrent	SD	4.99
	35	33	Male	Head	Recurrent	PD	1.68
<b>GEM-CAP</b>							
	19	45	Male	Body/tail	Metastatic	PR	7.26
	22	48	Male	Body/tail	Metastatic	NA	7.32
<b>FOLFOX</b>							
	6	72	Male	Head	Recurrent	SD	5.78
	7	52	Male	Head	Metastatic	PR	5.62

PFS, progression-free survival; 5-FU, 5-fluorouracil; SD, stable disease; PD, progressive disease; PR, partial response; NA, not applicable; CR, complete response; GEM-CAP, gemcitabine plus capecitabine; FOLFOX, oxaliplatin plus 5-FU/leucovorin.